Can peptides regenerate cartilage?
Bottom line: No peptide sold online has been shown to regrow enough joint cartilage to reliably reduce pain and restore function in humans. One experimental protein, sprifermin, increased MRI-measured knee-cartilage thickness in a large trial—but did not improve overall symptoms more than placebo.
- Collagen peptides
- May improve knee-pain symptoms; a 2025 trial did not improve joint-space width.
- Semaglutide
- Improved knee pain in people with obesity; STEP 9 did not establish cartilage regrowth.
- Sprifermin
- Changed MRI-measured cartilage thickness; overall WOMAC symptoms did not significantly improve versus placebo.
- BPC-157
- Cartilage regeneration has not yet been tested in a dependable human trial.
Three claims that should not be confused
- Less pain: a person reports that the joint hurts less.
- A structural change: an MRI or X-ray measurement changes.
- Useful regeneration: new or preserved tissue produces lasting improvement in how the person feels and functions.
A clinic may use the word “regeneration” after showing an animal experiment, a laboratory mechanism, or an image. None of those automatically proves that an older adult will walk farther, sleep better, or delay joint replacement.
What collagen studies show
An updated meta-analysis of 11 randomized trials involving 870 participants favored collagen for knee-arthritis pain and function. That is a symptom result, not proof that cartilage grew back.
A separate 2025 randomized trial followed 80 adults with early knee osteoarthritis for 180 days. Low-molecular-weight collagen peptides improved pain and function more than placebo, but joint-space width and inflammatory markers did not significantly improve. The fair reading is possible symptom relief with no demonstrated structural rebuilding.
What semaglutide shows
STEP 9 enrolled 407 adults who had obesity and painful knee osteoarthritis. At 68 weeks, semaglutide produced greater weight loss and greater pain improvement than placebo. The trial gives people in that specific group a meaningful result to discuss with a clinician. It does not show that semaglutide directly rebuilt cartilage.
The important sprifermin exception
Sprifermin is recombinant human fibroblast growth factor 18, an experimental protein injected into the knee—not the same thing as an online vial marketed for self-directed “healing.”
In the 549-person FORWARD randomized trial, the highest sprifermin schedules increased total femorotibial cartilage thickness on MRI by about 0.04 to 0.05 millimeters versus placebo after two years. But the overall WOMAC symptom scores were not significantly better than placebo. The study authors called the clinical importance of the structural result uncertain.
This matters because it is the strongest cartilage-thickness result in this group of interventions, yet even here the image and the patient experience did not clearly move together.
Where BPC-157 research stands
BPC-157 has interesting rodent tissue-repair results and a recruiting Phase 2 human hamstring trial. Human knee studies have not yet measured whether it changes cartilage, pain, or function. The mechanism is promising; the size of any arthritis benefit remains open.
Our verdict: Ask any clinic using the word “regenerate” to name the completed human trial, the exact product, the number of participants, the measured structural change, and whether people actually felt or functioned better. If those answers are missing, the claim is ahead of the evidence.
Questions to take to a clinician
- What is the most likely cause of my joint pain, and what else could mimic it?
- Is the goal less pain, better function, slower structural damage, or all three?
- Was this exact treatment tested in people like me?
- What result would make us continue, change, or stop the plan?
- What are the approved and better-tested alternatives?
Primary sources
- Hochberg MC, et al. FORWARD randomized clinical trial of sprifermin. JAMA, 2019. PMID 31593273.
- Randomized trial of low-molecular-weight collagen peptides in knee osteoarthritis. Frontiers in Nutrition, 2025. PMID 40977985.
- Updated meta-analysis of collagen supplementation for knee osteoarthritis. Journal of Orthopaedic Surgery and Research, 2024. PMID 39212129.
- STEP 9 randomized trial of semaglutide in obesity and knee osteoarthritis. New England Journal of Medicine, 2024. PMID 39476339.
- FDA briefing document on BPC-157-related bulk drug substances. July 2026.
Published and evidence reviewed August 11, 2026. This is an evidence summary, not a diagnosis or treatment recommendation. Report a correction or new study.